Pharma Pricing and Reimbursement and Market Access Risk Scores (MARS) by Region - Overview of 2022 and Outlook for 2023

Pharma Pricing and Reimbursement and Market Access Risk Scores (MARS) by Region - Overview of 2022 and Outlook for 2023

Summary

GlobalData is pleased to present an executive summary of healthcare expenditure and pharmaceutical sales forecasts from its Q1 2023 forecast cycle.

The latest/global outlook for pricing and market access reforms in the pharmaceutical industry, including HTA reforms, IRP, clawbacks and much more. The report is powered by unique price intelligence and data to understand price cuts/increases and reimbursement restrictions around the world.

Key Highlights

The global market access risk score (MARS) has significantly increased in the first quarter of 2023 while remaining at an elevated risk level of 2.371, a 14.6% increase compared to last quarter.

For this quarterly update, the team has updated the events risk ratings for the past 3 months captured in our qualitative measures, along with macroeconomic, political, legal environment, demographic and social structure effectiveness, technology and infrastructure, and environment risks. These factors are reflected in the quantitative measures.

This month, GlobalData has also included a look back at the key pricing and market access trends of 2022 and how they will define the outlook of the pharma industry in 2023.

Scope

• Global coverage of key P&R and health policy reforms, pricing trends and more.

• Global outlook for market access and pricing & reimbursement (P&R) in the pharmaceutical industry, including key trends that are driving opportunities and risk. The report includes our annual outlook for 2023 on the P&R and HTA policy reform environment and how that is driving GlobalData’s unique market access risk scores (MARS) which provide a quantitative framework for pricing/market access professionals to assess risk and opportunities around the world.